Back to top
more

Ritter Pharmaceuticals, Inc. (RTTR)

(Delayed Data from NSDQ)

$0.75 USD

0.75
64,642

-0.03 (-3.83%)

Updated May 3, 2019 04:13 PM ET

After-Market: $0.75 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Qualigen Therapeutics, Inc. [RTTR]

Reports for Purchase

Showing records 21 - 40 ( 56 total )

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 21

11/13/2018

Company Report

Pages: 8

3Q18 Recap: Trial Underway with Runway to Data

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 22

10/15/2018

Company Report

Pages: 4

Additional RP-G28 Mechanistic Data Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 23

08/16/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 24

08/15/2018

Company Report

Pages: 4

2Q 2018 Financial Results Reported; Wider-Than- Projected Net Loss as Pivotal Trial Advances; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 25

08/15/2018

Company Report

Pages: 8

2Q18 Recap - Trial Underway, Data Likely in 2H19

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 26

06/28/2018

Company Report

Pages: 5

First RP-G28 Phase 3 Trial Kicks Off; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 27

06/06/2018

Company Report

Pages: 5

RP-G28 Clinical Program Showcased at Digestive Disease Week; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 28

05/29/2018

Company Report

Pages: 4

Respected Biopharma Executive Appointed as New Chief Financial Officer; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 29

05/29/2018

Company Report

Pages: 4

1Q 2018 Financial Results Reported; RP-G28 Phase 2b Data Presentation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 30

05/17/2018

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 31

05/16/2018

Company Report

Pages: 8

1Q18 Recap - P3 Trial Start Imminent

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 32

03/20/2018

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 33

03/19/2018

Company Report

Pages: 8

Q17 Recap - P3 Patient Screening to Start in 2Q18

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 34

03/12/2018

Company Report

Pages: 4

Phase 2b Microbiome Data Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 35

03/05/2018

Company Report

Pages: 4

1-for-10 Reverse Stock Split Authorized; Adjusting Price Target to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 36

11/01/2017

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 37

10/31/2017

Company Report

Pages: 8

3Q17 Recap - Cash Replenished; Trial to Start in 1H18

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 38

10/24/2017

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 39

10/23/2017

Company Report

Pages: 7

Version 2.0 Ready for Launch

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Qualigen Therapeutics, Inc.

Industry: Medical - Drugs

Record: 40

10/23/2017

Company Report

Pages: 13

RP-G28 Clinical Development Pathway Clarified; Financing Complete; Reducing Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 50.00

Research Provided by a Third Party
// eof